Spectral Medical (Edtxf) (TSE:EDT) has released an update.
Spectral Medical Inc. has reported notable progress in the Tigris trial for septic shock treatment, enrolling 97 of the targeted 150 patients, while also extending its commercial partnership with Baxter for ten years post-FDA approval. The company’s collaboration with Baxter has resulted in a milestone payment, bolstering Spectral’s non-dilutive funding sources. With additional clinical sites being added, Spectral is poised to complete the Tigris trial, which could significantly impact the treatment of sepsis upon FDA approval.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.
